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The work carried in the research tenure has been compiled in the form of a thesis entitled “Synthesis and Anticancer Activity of New Pyrrolo[2,1-c][1,4]benzodiazepine and Chalcone Derivatives”. The main aim of this work is design and synthesis of biologically active 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates and anilino substituted pyrimidine-pyrrolobenzodiazepine conjugates, to explore their DNA binding ability and anticancer activity. Furthermore, imidazopyridine/pyrimidne chlacone derivatives have been prepared and evaluated for their anticancer activity and apoptosis inducing ability. The thesis has been divided into four chapters.

	Chapter I: This chapter gives the general introduction about cancer chemotherapy, covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics, and the objectives of the present work.
	Chapter II: This chapter describes the synthesis of a series of 3,5-diaryl isoxazoline/isoxazole-PBD conjugates connected through simple alkane spacers and these conjugates have been evaluated for their biological activity. This chapter is mainly focused on the mitochondrial mediated apoptotic pathway responsible for the significant anticancer activity.
	Chapter III: This chapter deals with the synthesis of new PBD hybrids by linking anilino substituted pyrimidines through alkane spacer to the C8-position of the A ring of PBD scaffold. The present chapter is mostly focused on the DNA-binding affinity and anticancer activity of the newly synthesized PBD hybrids. 
	Chapter IV: This chapter illustrates design, synthesis and biological evaluation of imidazopyridine/pyrimidine chlacone derivatives as potent anticancer agents. Further, these derivatives have been evaluated for their cell cycle effects and cell cycle regulatory proteins on MCF-7 cell lines.

	Introduction
This chapter describes the general introduction about pyrrolobenzodiazepines and the objectives of the present work.
	Pyrrolo[2,1-c][1,4]Benzodiazepines 
	Cancer is a group of diseases characterized by uncontrolled growth or spread of abnormal cells. Since it involves the conversion of any normal cells to a cancerous cell showing tandem replication and cell divisions at much faster rate in comparison to the normal cells and thus provides a potential target area for the development of chemotherapeutic agents. It is now clear that chemotherapy’s most effective role in solid tumours is as an adjuvant to initial therapy by surgical or radiotherapeutic procedures. Chemotherapy becomes critical to effective treatment because only systemic therapy can attack micrometastases. These agents can be categorized into functional sub groups: alkylating agents, antimetabolites, antibiotics, and antimitotics. The pyrrolo[2,1-c][1,4]-benzodiazepines (PBDs) belonging to the class of DNA-interactive antitumour antibiotics have the potential as regulators of gene expression with possible therapeutic application in the treatment of genetic disorders including cancer. The first PBD antitumour antibiotic anthramycin has been described by Leimgruber coworkers about 40 years back, and since then a number of compounds have been developed based on PBD ring system leading to DNA binding ligands. 
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of potent naturally occurring low molecular weight antitumour antibiotics originally isolated from various Streptomyces species. Their common interaction with DNA has been extensively investigated and it is considered unique since they bind within the minor groove of DNA forming a covalent aminal bond between the C11-position of the central B-ring and the N2 amino group of guanine base. A number of naturally occurring and synthetic compounds based on PBD ring system, such as anthramycin, tomaymycin, DC-81 and its dimers (presently, one of the dimer SJG-136 is under clinical evaluation), have shown varying degrees of DNA binding affinity and anticancer activity.
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Chemotherapy is often the treatment of choice for many types of cancer as a result the search for newer chemotherapeutic agents still plays a major role in the fight against cancer. In recent years there has been increasing interest in the design of conjugate molecules that could act in a specific manner on more than one target. The development of such conjugates lowers the risk of drug-drug interaction in comparison to cocktails but could also enhance the efficacy as well as improve the safety aspects in relation to the drugs that interact on a single target. Several conjugate compounds, in which a known antitumour compound or some simple active moiety tethered to PBD, have been designed, synthesized and evaluated for their biological activity. Recently, Wang and co-workers have synthesized indole-PBD conjugates as potential antitumour agents and a correlation between antitumour activity and apoptosis has been well explained. More recently, we have also reported some of the PBD conjugates that demonstrated potent apoptotic activity through mitochondrial-mediated pathway.
In continuation of these efforts, we herein report the synthesis and biological evaluation of some new conjugates wherein 3,5-diaryl-isoxazoline/isoxazole moieties have been linked to the pyrrolo[2,1-c][1,4]benzodiazepine ring system and these compounds have been evaluated for their biological activity. An attempt, based on the in vitro cytotoxic activity exhibited in these compounds made to rationalize their mechanism of action through cell cycle analysis and DNA interaction studies. Cell cycle phase distribution and apoptosis is measured using flow cytometry. The DNA binding characteristics of these conjugates have been evaluated by thermal denaturation studies. A molecular modeling study has been carried out for a set of compounds 29af and 32ag and calculated their binding score. Further MD simulations have also been carried out for the compounds 29a, 32d and 32e. The representative compounds 29b and 32d of this series have been tested against a panel of 60 human cancer cell lines. Further, compounds 32ce induce marked influence on the cell cycle phase distributions in A-375 cells, followed by the induction of apoptosis through mitochondrial mediated pathway.

	Synthesis of 3,5-diarylisoxazoline/isoxazole linked pyrrolobenzodiazepine (PBD) conjugates	
Synthesis of 3,5-diaryl-isoxazoline/isoxazole -PBD conjugates (29af and 32ag) has been carried out by employing the commercially available vanillin (1) as the starting material. Oxidation of vanillin to form the corresponding carboxylic acid followed by acid-catalyzed esterification with methanol provided methyl benzoate in quantitative yield. This is followed by benzylation and nitration by employing the literature method provides 4-benzyloxy-5-methoxy-2-nitrobenzoic acid (6). Later this has been coupled to L-proline methyl ester to afford the compound 7, which upon reduction with DIBAL-H produces the corresponding aldehyde 8. This product upon protection with EtSH/TMSCl gives compound 9, which on debenzylation provides the hydroxyl intermediate compound 10 which upon etherification by dibromoalkanes provide compounds11ac (Scheme 1). 


The synthesis of 3,5-diaryl-isoxazoline/isoxazole derivatives (17a,b, 22 and 26a,b) has been carried out from aldehydes 12, 14a,b and 18 as the starting materials. Reaction of these aldehydes with hydroxylamine in a MeOH/H2O (3:1) solution produced the corresponding oximes 13, 24a,b and 19. Olefins 15a,b and 20 have been obtained by the reaction of aldehydes 14a,b and 12 with methyltriphenylphosphonium bromide, in the presence of sodium hydride. Then these olefins 15a,b and 20 have been coupled to oximes 13 and 19 to provide the corresponding TBDMS protected isoxazolines 16a,b and 21. Similarly, TBDMS protected isoxazoles 25a,b have been prepared by employing alkyne 23 and oximes 24a,b. Then, these compounds 16a,b, 21 and 25a,b upon deprotection with tetrabutylammonium fluoride gave the desired precursors (17a,b, 22 and 26a,b) as shown in Schemes 2 and 3. 



The synthesis of C8-linked 3,5-diaryl-isoxazoline/isoxazole-PBD conjugates (29a–f and 32a–g) has been carried out from the (2S)-N-{4-[3-bromoalkoxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal (11a–c), and these were prepared by the methods reported in our earlier studies. These upon etherification with the 3,5-diaryl-isoxazoline/isoxazole intermediates using K2CO3 in acetone provided the corresponding nitro thioacetals (27a–f and 30a–g). These nitro thioacetals 27a–f and  30a–g are reduced to the amino thioacetals 28a–f and  31a–g by employing SnCl2.2H2O in refluxing MeOH and then cyclized by treatment with HgCl2 and CaCO3 in MeCN-H2O to yield the target products 29a–f and 32a–g (Schemes 4 and 5).






The thermal denaturation studies show that hybrid agents (29af and 32ag) possess good DNA binding ability compared to DC-81. Our findings suggested that these conjugate agents bind to DNA more efficiently than DC-81. In addition, molecular modeling study is carried out for a set of 3,5-diaryl-isoxazoline/isoxazole-PBDs (29af and 32ag) in order to rank them through their complementarity to the CGCGATCGCG, according to their interaction energies with B-DNA. The optimal number of methylene linkers calculated from the GOLD docking and the experimental numbers are in reasonably good agreement.
        Compounds 29a, 29cf, 32ac and 32eg have exhibited significant anticancer activity against eleven cancer cell lines with GI50 values ranging from <0.1 to 2.15 M in comparison to adriamycin (GI50 from 0.1–14.0 M). According to the in vitro screening data, compound 32d possess significant cytotoxicity against all the cancer cell lines with GI50 values ranging from 0.09 to 0.58 M and the mean GI50 value for the compound 32d is 0.25 M, which exhibits an interesting profile of activity for various cell lines, indicating that this compound 32d has the potent broad-spectrum anticancer activity. Further, compounds 32ce induced strong sub G1/G0 arrest of the cell cycle followed by apoptosis, in A-375 cells. It is also observed from the results of detailed biological assays that the p53 levels are enhanced when treated with compounds 32ce. Moreover, release of cytochrome c is as well observed for these conjugates (32ce), thus indicating the involvement of mitochondrial pathway. Concomitant with this an increase in the levels of active caspase-3 and cleavage of PARP is also observed with all these conjugates, particularly it was more pronounced in case of 32c. Finally, it may be concluded that one of the PBD conjugate 32c prepared in the present investigation has the potential to be taken up for preclinical studies either alone or in combination with existing therapies (Eur. J. Med. Chem. 2010, 45, 39243937, 
Patent Publication No.WO 2009/118748 A1).


Many chemotherapeutics are known to induce apoptosis, which is a promising strategy for cancer drug discovery. Among the different approaches available to promote apoptosis, the development of conjugates is one of the main strategies. From the previous studies it is known that anilino primidines are reported to possess apoptosis inducing ability, similarly some of the PBD conjuagtes are also known to induce apoptosis.
In an effort to establish new candidates with improved anticancer activity and apoptosis inducing ability, pyrrolobenzodiazepine derivatives bearing substituted anilino pyrimidine moiety have been synthesized and their DNA interaction has been evaluated by thermal denaturation and enzyme inhibition studies. The cytotoxic studies of the hybrid agents on human cancer cell lines indicate most of the hybrids induced higher cytotoxicity. In view of promising activity it has been considered of interest to investigate their role in cell proliferation and apoptosis by using the human melanoma cell line A-375.
	Synthesis of C8-Linked Pyrrolo[2,1-c][1,4]benzodiazepine Hybrids with Anilino Substituted Pyrimidine
Synthesis of pyrimidine intermediates 8a,b and 10 has been carried out from the compounds 6a,b which have been prepared by the literature method. Compounds 6a,b have 
been coupled to 5-bromo valeryl chloride (7) to provide compounds 8a,b whereas this 6a has been treated with 4-(bromomethyl)benzoyl chloride (9) to obtain compound 10 as shown in Scheme 1.

Synthesis of (2S,4S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl)-4-fluoropyrrolidine-2-carboxaldehyde diethyl thioacetal (15) has been carried out from the 4-benzyloxy-5-methoxy-2-nitrobenzoic acid 11, and this has been prepared by the methods reported in our earlier studies. This has been coupled with trans-4-hydroxyproline methyl ester to afford the (2S,4R)-N-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)-4-hydroxy-pyrrolidine-2-carboxylate (12), which upon treatment with DAST in CH2Cl2 produces the (2S,4S)-N-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)-4-fluoropyrrolidine-2-carboxylate (13). Whereas, (2S,4S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl)-4-fluoropyrrolidine-2-carboxaldehyde diethyl thioacetal (14) has been prepared by literature method, which upon debenzylation gives the target compound 15. The hydroxy nitro thioacetal (18) has been prepared by previous literature method (Scheme 2).

Synthesis of C8-linked anilino substituted pyrimidine–PBD conjugates (21ac and 24a,b) has been carried out by employing the hydroxy nitrothioacetal compounds 15 and18 as the starting materials, which has been prepared by previously reported methods. These upon etherification with the intermediates 8a,b and 10 using K2CO3 in acetone provided the corresponding nitro thioacetals (19ac and 22a,b). These nitro thioacetals 19ac and 22a,b are reduced to the amino thioacetals 20ac and 23a,b by employing SnCl2.2H2O in refluxing MeOH and then cyclized by treatment with HgCl2 and CaCO3 in MeCN-H2O to yield the target products 21ac and 24a,b (Schemes 3, 4).




Biological Activity of C8-Linked Pyrrolo[2,1-c][1,4]benzodiazepine 
Conjugates              
Compounds 21ac and 24a,b have been evaluated for their cytotoxicity in selected human cancer cell lines of breast, oral, ovary, colon, lung, prostate and cervix by using sulforhodamine B (SRB) method. These compounds exhibiting GI50 ≤ 10-5 M (10 µM) are considered to be active on the respective cell lines. These compounds have exhibited broad-spectrum activity in all the cell lines employed and the activity of the compounds ranged from GI50 <0.1 to 2.7 µM. Adriamycin is employed as the positive control that demonstrated GI50 values in the range of <0.1 to 2.1 µM, whereas DC-81 have shown GI50 values in the range of 0.11 to 2.37 µM. 
Thermal denaturation studies showed that these compounds stabilized the thermal helix coil or melting stabilization (ΔTm) for the CT-DNA duplex at pH 7.0, where PBD/DNA molar ratio is 1:5. Interestingly, all PBD conjugates (21ac and 24a,b) elevate the helix melting temperature of CT-DNA in the range of 1.27.1 C at 0 h and also examined after 18 h incubation at 37 o C. Compounds 24a,b have shown highest Tm ranges from 5.05.8 C at 0 h and increased up to 6.87.1 C after 18 h incubation. All the compounds 21ac and 24a,b have shown better fit in the minor groove of DNA, leading to enhanced binding affinity compared to DC-81.
The FACS analysis has shown more population in sub-G1 phase indicating that all these PBD conjugates have apoptosis inducing ability. It has been observed from the results that the p53 levels are enhanced. Pronounced increase in the levels of cytosolic cytochrome c and cleaved PARP is observed particularly, it is more pronounced in case of 24b. Hence, these PBD conjugates induce apoptosis by acting through the mitochondrial mediated pathway (Bioorg. Med. Chem. Lett. 2010, 20, 52325236).



In continuation to our efforts on the design of new anticancer agents, imidazopyridine/pyrimidine chalcone derivatives have been synthesized. These new chalcone derivatives have been evaluated for their anticancer activity, cell cycle effects and cell cycle regulatory proteins.
	Synthesis of imidazopyridine/pyrimidine chalcone derivatives 
The imidazo[1,2-a]pyridine chalcone derivatives (7ae) have been prepared by  the Claisen-Schmidt condensation of 3,4,5-trimethoxyacetophenone (6) with substituted imidazo[1,2-a]pyridine aldehydes (5ae) in the presence of KOH (50%). The imidazo[1,2-a]pyridine aldehydes (5ae) have been obtained by means of the Vilsmeier reaction on the corresponding imidazo[1,2-a] pyridines (4ae), that have been obtained from compounds 3ae. The intermediate compounds 3ae were obtained by the reaction of appropriate 2-aminopyridine (1) and bromoketones (2ae). The (2E)-3-(2-(trifluoromethyl)H-imidazo[1,2-a]pyridin-3-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (9) has been prepared by coupling of 3,4-dimethoxyacetophenone (8) with 2-(trifluoromethyl)H-imidazo[1,2-a]pyridine-3-carbaldehyde (5e) as shown in Scheme 1.

The synthesis of imidazo[1,2-a]pyrimidine chalcone derivatives (15ac) is outlined in Scheme 2. Compounds 11ac have been treated with 2-amino pyrimidine to give compounds 12ac.These intermediate compounds 12ac reacted with hydrochloric acid to obtain the imidazo[1,2-a]pyrimidines (13ac). The imidazo[1,2-a]pyrimidine aldehydes (14ac) have been obtained by means of the Vilsmeier reaction on the corresponding imidazo[1,2-a] pyrimidines (13ac). These aldehydes (14ac) have been coupled with 3,4,5-trimethoxy acetophenone (6) to give imidazo[1,2-a]pyrimidine chalcones (15ac)  as shown in Scheme 2.  

The representative compounds 7a, 7ce, 9 and 15a,b were evaluated for anticancer activity in the standard 60 human cancer cell lines derived from nine cancer types (leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancers). These compounds showed significant anticancer activity in a large number of cell lines with GI50 values ranging from 0.28 to 30.0  Specifically, compound 9 exhibited promising anticancer activity against CCRF-CEM, K-562, SR, RPMI-8226 (leukemia cancer), NCI-H460 (non small cell lung cancer), HCC-2298, HCT-116, KM12 (colon cancer), IGROV1 (ovarian cancer), DU-145 (prostate cancer), MCF-7 (breast cancer) and LOXMVI, UACC-257 (melanoma cancer) cell lines.
The cell-cycle distribution is analyzed by treating MCF-7 cells at 4 µM concentration for 24 h by flowcytometry. Results indicated 85.55% (7a), 92.41% (7d), 95.24% (7e), 97.86% (9), 90.04% (15a), 74.16% (15b) of cells in G0/G1 phase respectively, whereas, positive control doxorubicin and control cells showed 94.85% and 64.04% respectively in G0/G1 phase. Among all the compounds tested compound 9 could be considered as the most effective derivative to produce cell cycle arrest.
It is also observed from the results of the detailed biological assays that the down regulation of G1 phase cell cycle regulatory proteins such as cyclin D1, E1, and CDK2 and up regulation of G1/S check point associated tumor suppressor protein p27 thus suggesting that these proteins are responsible for cell cycle blockade at G1 phase in compound 9. Moreover, procaspase-9 level was decreased and TNFR1 protein level was increased, thus indicating that compound 9 followed extrinsic apoptotic pathway (Med. Chem. Comm. 2010, Accepted).
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